Global Humanized Mouse And Rat Model Market Size By Type of Model, By Application, By End-User, By Geographic Scope And Forecast

Humanized Mouse And Rat Model Market Size And Forecast

Humanized Mouse And Rat Model Market size was valued at USD 135.23 Million in 2024 and is projected to reach USD 259.09 Million by 2031, growing at a CAGR of 9.34% from 2024 to 2031.

The humanized mouse and rat models are genetically modified animals that express human genes, tissues, or cells, resulting in a model system that closely resembles human physiology and disease processes. These models are useful in biomedical research, helping to understand human diseases, create drugs, and test new treatments. Humanized mice, for instance, are used to study immune system problems, cancer, and infectious diseases, whereas humanized rats can help researchers understand neurological and metabolic issues. These models, which replicate human-specific traits, assist researchers in better understanding disease causes and assessing the efficacy and safety of prospective treatments before proceeding to human clinical trials.

Humanized mouse and rat models show great promise as genetic engineering and biotechnology improve. Improvements to these models are projected to increase their relevance and accuracy, resulting in more detailed simulations of human diseases and better forecasts of treatment results. Emerging technologies, including CRISPR-Cas9 gene editing and stem cell applications, are likely to broaden the capabilities of humanized models, enabling the development of more sophisticated and disease-specific models. Furthermore, combining improved imaging techniques with high-throughput screening methods may increase the applicability of these models in personalized medicine, paving the path for more successful and individualized therapeutic approaches.

Global Humanized Mouse And Rat Model Market Dynamics

The key market dynamics that are shaping the global humanized mouse and rat model market include:

Key Market Drivers:

Increasing Prevalence of Cancer and Demand for Personalized Medicine: The World Health Organization reports that cancer is the top cause of mortality globally, with approximately 10 million deaths expected in 2020. This has led to a growing need for individualized therapy. The expanding cancer burden is increasing the need for humanized mouse models in oncology research and medication development."

Rising Investments in Pharmaceutical R&D: According to the Pharmaceutical Research and Manufacturers of America (PhRMA), biopharmaceutical businesses invested around USD 83 Billion in R&D in 2019. This significant investment is accelerating the use of advanced preclinical models, such as humanized mouse and rat models.

Growing Focus on Precision Medicine: The National Institutes of Health's "All of Us" Research Program, established in 2018, aims to collect data from one million or more US residents to speed up research and improve health outcomes. This project reflects the growing emphasis on precision medicine, which largely relies on improved animal models for translational research.

Key Challenges:

Ethical Concerns: Concerns about the use of genetically modified animals influence the acceptance and regulation of humanized models. These considerations include animal welfare and the possibility of unforeseen repercussions in animal-human research. Sricter regulations and norms are implemented, potentially slowing research development and complicating the process of gaining necessary model approvals.

Limited Availability of Custom Models: Custom humanized models tailored to specific research objectives are only available in limited quantities. Many researchers require specialized models to examine specific diseases or treatment reactions, which may not be readily available or cheap. This constraint can stymie research progress and postpone the development of individualized therapeutics because researchers may have to rely on less appropriate or generic models.

High Cost of Development: Humanized mouse and rat model development is expensive due to complicated genetic engineering and extended maintenance requirements. This high cost makes it difficult for smaller research institutes and biotech startups to obtain funding. The market for these models is confined since fewer businesses can afford to use or develop such models, limiting overall growth potential and innovation in this field.

Market Fragmentation: The humanized mouse and rat model market is fragmented, with multiple firms providing various types of models and services. This fragmentation can impede market consolidation and collaboration, potentially leading to inefficiencies and duplicative efforts. Research progress may be slowed, and the creation of novel models and therapies may be hampered by a lack of consistent industry standards and practices.

Key Trends:

Expansion of Research in Immunology and Oncology: The increase in research in immunology and oncology is driving up demand for humanized models. These domains benefit from models that can accurately simulate human immune responses and cancer progression. Humanized mouse and rat models provide important insights into disease mechanisms and therapeutic efficacy, allowing for advances in immunotherapy and cancer research. This tendency increases the demand for more sophisticated and accurate model systems.

Development of Humanized Models for Rare Diseases: The development of humanized models for rare and complex diseases is gaining traction, owing to the need for better research tools for these conditions. Humanized models can duplicate specific illness traits and reactions, allowing researchers to examine rare diseases that are often difficult to model. This approach promotes market expansion by broadening the scope of disorders that may be studied and treated with precision medicines.

Advancement in Genetic Engineering Techniques: Genetic engineering tools, such as CRISPR-Cas9, are being developed to create more precise and adaptable humanized mouse and rat models. These technologies enable the development of models with specific human gene variants and illness situations. As a result, the accuracy and relevance of these models in simulating human diseases have greatly improved, resulting in increased demand from researchers looking for more trustworthy preclinical testing methods.

Growing Investment in Biotechnology and Pharmaceuticals: Increased investment in biotechnology and pharmaceutical research is propelling the humanized mouse and rat model market. With greater funds available, research institutes and companies are using advanced models for drug discovery and development. This financial support enables the creation of creative models and the study of new therapeutic techniques, thereby advancing research and driving market growth.

Global Humanized Mouse And Rat Model Market Regional Analysis

Here is a more detailed regional analysis of the global humanized mouse and rat model market:

North America:

North America is projected to dominate the humanized mouse and rat model market owing to its broad network of research institutions, pharmaceutical businesses, and biotechnology firms. This leadership is supported by considerable investments in biomedical research, as indicated by the National Institutes of Health's (NIH) allocation of roughly USD 45.1 Billion for biomedical research in fiscal year 2023. A significant amount of this money is allocated to studies with humanized animal models, emphasizing their importance in improving medical research.

Furthermore, biopharmaceutical businesses in the United States invested around USD 102.3 Billion in R&D in 2021, with a large portion devoted to preclinical research employing humanized models, representing a 7.9% increase over the previous year. This expenditure demonstrates the increasing reliance on advanced preclinical models for drug research.

The rising prevalence of complicated diseases in North America fuels the need for improved research techniques. With an anticipated 1.9 million new cancer cases expected in the United States by 2023, there is an increased demand for humanized mice and rat models to develop targeted treatments and immunotherapies. The United States Food and Drug Administration (FDA) likewise endorses this trend, advocating the use of humanized animal models to improve the predictive value of preclinical studies for human clinical trials. This governmental support, combined with a high illness burden and significant R&D spending, guarantees that North America's market for humanized models and rat market will expand in the future years.

Asia Pacific:

The Asia Pacific region is seeing significant growth in the humanized mouse and rat model market as a result of large investments in healthcare infrastructure, increasing research activities, and the expansion of pharmaceutical businesses. Cancer, a major health concern in the region, with roughly 8.8 million new cases reported in 2018, is driving the demand for advanced preclinical models for cancer research and therapeutic development.

The region's pharmaceutical industry is also rapidly expanding, with India's market predicted to reach $65 billion by 2024 and USD 120-130 Billion by 2030, increasing the demand for improved preclinical models to aid in drug discovery. Furthermore, the Asia Pacific Contract Research Organization (CRO) market is expected to rise, reflecting the increasing usage of humanized mouse and rat models in pharmaceutical research. The cost-effective research environment in Asia Pacific, as compared to North America and Europe, is attracting pharmaceutical businesses looking to optimize R&D spending and support regional market expansion.

Global Humanized Mouse And Rat Model Market: Segmentation Analysis

The Global Humanized Mouse And Rat Model Market is Segmented on the basis of Type of Model, Application, End-User, And Geography.

Humanized Mouse And Rat Model Market, By Type of Model

• Genetic Humanized Mouse And Rat Models
• Cell-Based Humanized Mouse And Rat Models
• Pharmacological Humanized Mouse And Rat Models

Based on Type of Model, the Humanized Mouse And Rat Model Market is bifurcated into Genetic Humanized Mouse And Rat Models, Cell-Based Humanized Mouse And Rat Models, and Pharmacological Humanized Mouse And Rat Models. Genetic humanized mouse and rat models currently lead the market due to can give more precise and regulated models for researching human diseases. These models enable researchers to directly explore the impact of specific human genes on illness onset and progression. Cell-based humanized mouse and rat models are emerging as the fastest-growing group, thanks to advances in cell transplantation procedures and rising acknowledgment of their utility in researching complicated disorders involving many cell types. These models are more adaptable and cost-effective than genetic models, making them suitable for a broader range of research applications.

Humanized Mouse And Rat Model Market, By Application

• Oncology Research
• Immunology and Infectious Diseases
• Neuroscience
• Toxicology
• Hematopoiesis

Based on Application, the Humanized Mouse And Rat Model Market is segmented into Oncology Research, Immunology and Infectious Diseases, Neuroscience, Toxicology, and Hematopoiesis. Oncology research dominates the humanized mouse and rat model market due to the large unmet medical demand for new cancer treatments. These models are critical for understanding the underlying biology of cancer, generating new treatments, and assessing their efficacy. Immunology and infectious diseases are emerging as the fastest-growing area, driven by the rising prevalence of infectious diseases and the need for more effective immune therapy. Humanized models are critical for investigating immune responses to infections, creating vaccinations, and testing immunotherapies.

Humanized Mouse And Rat Model Market, By End-User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutions
• Contract Research Organizations (CROs)

Based on End-User, the Humanized Mouse And Rat Model Market is segmented into Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, and Contract Research Organizations (CROs). Pharmaceutical and biotechnology industries dominate the humanized mouse and rat model industry due to their considerable research and development operations aimed at medication discovery and development. These firms use these models to assess the efficacy and safety of new medication candidates. Academic and research institutions are emerging as the fastest-growing group, thanks to increased research funding and a rising acknowledgment of the value of humanized models in biomedical research. These institutes make major contributions to the development of novel models and approaches, hence broadening the applicability of humanized mice and rats in a variety of research fields.

Humanized Mouse And Rat Model Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Humanized Mouse And Rat Model Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the humanized mouse and rat model market, owing to the presence of major pharmaceutical companies, research institutions, and government financing for biomedical research. However, the Asia Pacific area, particularly China and India, is seeing the most rapid expansion as a result of increased investments in healthcare facilities, increased research efforts, and expanding pharmaceutical companies. This region is fast catching up in terms of research capability and cost-effective research opportunities, attracting global pharmaceutical corporations.

Key Players

The "Global Humanized Mouse And Rat Model Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Yecuris Corporation, Hera BioLabs, Horizon Discovery Group plc, Champions Oncology, Inc., Transgenic, Inc., Crown Bioscience, Inc., AXENIS S.A.S, inGenious Targeting Laboratory, Vitalstar Biotechnology Co Ltd, Hera BioLabs, Harbour Antibodies BV, Charles River Laboratories, genOway, S.A., Horizon Discovery Group plc, Taconic Biosciences, Inc. and The Jackson Laboratory. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Humanized Mouse And Rat Model Market Recent Developments
• In January 2022, Taconic Biosciences, Inc. (US) announced the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
• In October 2021, The Jackson Laboratory (US) acquired Charles River Laboratories Japan, Inc. (Japan)'s Research Models & Services (RMS) business as a wholly owned subsidiary.
• In September 2021, Biocytogen (US) partnered with Envigo (US) to support the research applications of the triple immunodeficient B-NDG mice. Envigo is the sole supplier of B-NDG mice in the United States, Europe, and select APAC markets.
• In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US), a contract development and manufacturing organization (CDMO) that provides full manufacturing solutions for cell therapies. The acquisition broadened Charles River's expertise in the primary CDMO platforms for cell and gene treatments.